AR106756A1 - Compuestos y composiciones útiles para el tratamiento de trastornos relacionados con ntrk - Google Patents
Compuestos y composiciones útiles para el tratamiento de trastornos relacionados con ntrkInfo
- Publication number
- AR106756A1 AR106756A1 ARP160103546A ARP160103546A AR106756A1 AR 106756 A1 AR106756 A1 AR 106756A1 AR P160103546 A ARP160103546 A AR P160103546A AR P160103546 A ARP160103546 A AR P160103546A AR 106756 A1 AR106756 A1 AR 106756A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroalkyl
- monocyclic
- hydroxyalkyl
- heterocyclyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000002950 monocyclic group Chemical group 0.000 abstract 6
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 5
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- -1 -N(R1)(R1) Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- FXHJEQWDROLIGP-OAHLLOKOSA-N 5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidine-3-carbonitrile Chemical compound FC1=CC=C(F)C([C@@H]2N(CCC2)C2=NC3=C(C#N)C=NN3C=C2)=C1 FXHJEQWDROLIGP-OAHLLOKOSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, caracterizado porque: el anillo A se selecciona entre arilo monocíclico o bicíclico, heteroarilo monocíclico o bicíclico, cicloalquilo y heterociclilo; cada RA se selecciona en forma independiente entre arilo monocíclico o bicíclico, heteroarilo monocíclico o bicíclico, cicloalquilo monocíclico o bicíclico, heterociclilo monocíclico o bicíclico, C₁₋₆ alquilo, C₁₋₆ alcoxilo, halo, C₁₋₆ haloalquilo, C₁₋₆ haloalcoxilo, C₁₋₆ hidroxialquilo, C₁₋₆ heteroalquilo, -N(R¹)(R¹), nitro, ciano, -C(O)R¹, -OC(O)R¹, -C(O)OR¹, -SR¹, -S(O)₂R¹, -S(O)₂-N(R²)(R²), -(C₁₋₆ alquilen)-S(O)₂-N(R²)(R²), -C(O)-N(R²)(R²), -N(R²)(R²)-C(O)R¹, -(C₁₋₆ alquilen)-N(R²)-C(O)R¹, -NR²S(O)₂R¹, -P(O)(R¹)(R¹), y -OR¹; donde cada uno de arilo, heteroarilo, cicloalquilo, heterociclilo, alquilo, alcoxilo, haloalquilo, hidroxialquilo, heteroalquilo está sustituido en forma independiente con 0 - 5 instancias de Rᵃ; cada RB se selecciona en forma independiente entre C₁₋₆ alquilo, C₁₋₆ alcoxilo, halo, C₁₋₆ haloalquilo, C₁₋₆ haloalcoxilo, C₁₋₆ hidroxialquilo, C₁₋₆ heteroalquilo, -N(R¹)(R¹), nitro, ciano, y -OR¹; cada R¹ se selecciona en forma independiente entre hidrógeno, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ haloalcoxilo, C₁₋₆ hidroxialquilo, C₁₋₆ heteroalquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, y heterociclilalquilo, donde cada uno de C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ hidroxialquilo, C₁₋₆ heteroalquilo, cicloalquilo, cicloalquilalquilo, heterociclilo, y heterociclilalquilo está sustituido en forma independiente con 0 - 5 instancias de Rᵇ; cada R² se selecciona en forma independiente entre hidrógeno, C₁₋₆ alquilo, C₁₋₆ heteroalquilo; o 2 R² junto con el nitrógeno al cual están unidos forman un anillo heterociclilo sustituido con 0 - 5 instancias de Rᵇ; cada Rᵃ y Rᵇ se selecciona en forma independiente entre halo, ciano, hidroxilo, C₁₋₆ alquilo, C₁₋₆ alcoxilo, C₁₋₆ haloalcoxilo, -N(R)(R), -C(O)-N(R)(R), -N(R)(R)-C(O)R, y -(C₁₋₆ alquilen)-N(R)-C(O)R; cada R y R se selecciona en forma independiente entre hidrógeno y C₁₋₆ alquilo o C₁₋₆ hidroxialquilo; m es 0, 1, 2, 3, 4 ó 5; y n es 0, 1 ó 2; con la condición de que el compuesto no es (R)-5-(2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-carbonitrilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257476P | 2015-11-19 | 2015-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106756A1 true AR106756A1 (es) | 2018-02-14 |
Family
ID=57517997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103546A AR106756A1 (es) | 2015-11-19 | 2016-11-18 | Compuestos y composiciones útiles para el tratamiento de trastornos relacionados con ntrk |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10370379B2 (es) |
| EP (1) | EP3377497A1 (es) |
| JP (1) | JP2019500328A (es) |
| KR (1) | KR20180081790A (es) |
| CN (1) | CN108431008A (es) |
| AR (1) | AR106756A1 (es) |
| AU (1) | AU2016355196A1 (es) |
| BR (1) | BR112018010024A8 (es) |
| CA (1) | CA3005741A1 (es) |
| HK (1) | HK1259453A1 (es) |
| IL (1) | IL259164A (es) |
| MX (1) | MX2018006195A (es) |
| PH (1) | PH12018501065A1 (es) |
| RU (1) | RU2018122089A (es) |
| SG (2) | SG11201803920TA (es) |
| TW (1) | TWI733713B (es) |
| WO (1) | WO2017087778A1 (es) |
| ZA (1) | ZA201803530B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2916220T3 (es) | 2012-07-11 | 2022-06-29 | Blueprint Medicines Corp | Inhibidores del receptor de factor de crecimiento de fibroblasto |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| SG11201602937UA (en) | 2013-10-17 | 2016-05-30 | Blueprint Medicines Corp | Compositions useful for treating disorders related to kit |
| SMT202200292T1 (it) | 2013-10-25 | 2022-09-14 | Blueprint Medicines Corp | Inibitori del recettore del fattore di crescita dei fibroblasti |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| MX2018001032A (es) | 2015-07-24 | 2018-11-09 | Blueprint Medicines Corp | Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr. |
| WO2017035354A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| JP2019500328A (ja) | 2015-11-19 | 2019-01-10 | ブループリント メディシンズ コーポレイション | Ｎｔｒｋに関連する障害の治療のために有用な化合物及び組成物 |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| CA3020870C (en) | 2016-04-15 | 2024-04-30 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
| JP7278273B2 (ja) | 2017-10-18 | 2023-05-19 | ブループリント メディシンズ コーポレイション | アクチビン受容体様キナーゼの阻害剤としての置換ピロロピリジン |
| ES2970041T3 (es) | 2018-04-03 | 2024-05-24 | Blueprint Medicines Corp | Inhibidor de RET para su uso en el tratamiento del cáncer que tiene una alteración de RET |
| MA54092A (fr) | 2018-10-30 | 2021-09-08 | Kronos Bio Inc | Composés, compositions et procédés de modulation de l'activité de cdk9 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| RS64881B1 (sr) | 2019-04-12 | 2023-12-29 | Blueprint Medicines Corp | Kristalini oblici (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amin i načini pripreme |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| AU2020402942B2 (en) * | 2019-12-13 | 2023-05-11 | Scinnohub Pharmaceutical Co., Ltd | Fluorine-containing heterocyclic derivatives with macrocyclic structure and use thereof |
| CN112979654B (zh) * | 2019-12-16 | 2024-03-19 | 赛诺哈勃药业（成都）有限公司 | 杂芳基稠环化合物、其制备方法及应用 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| BR112022024382A2 (pt) | 2020-05-29 | 2023-05-02 | Blueprint Medicines Corp | Formas sólidas de pralsetinibe |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5251911A (en) | 1992-12-09 | 1993-10-12 | Blake Carlton E | Safety construction for passenger vehicle |
| EP0929553B1 (en) | 1996-10-02 | 2005-03-16 | Novartis AG | Pyrimidine derivatives and processes for the preparation thereof |
| PL224879B1 (pl) * | 2002-09-04 | 2017-02-28 | Pharmacopeia Drug Discovery Inc | Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja |
| US7329662B2 (en) * | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| CN102924458B (zh) | 2004-04-02 | 2014-11-05 | Osi制药有限责任公司 | 6,6-双环取代的杂双环蛋白激酶抑制剂 |
| CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
| WO2009032703A1 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| ES2900243T3 (es) | 2008-10-22 | 2022-03-16 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]pirimidina sustituidos como inhibidores de trk quinasa |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| EP2566866A1 (en) | 2010-05-05 | 2013-03-13 | Vertex Pharmaceuticals Incorporated | 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| CN102241678B (zh) * | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | 含有脂环结构化合物的抗肿瘤作用与应用 |
| ES2916220T3 (es) | 2012-07-11 | 2022-06-29 | Blueprint Medicines Corp | Inhibidores del receptor de factor de crecimiento de fibroblasto |
| WO2014036387A2 (en) | 2012-08-31 | 2014-03-06 | The Regents Of The University Of Colorado | Methods for diagnosis and treatment of cancer |
| JP6457942B2 (ja) * | 2012-10-05 | 2019-01-23 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｇｄｆ−８阻害剤 |
| HK1214830A1 (zh) * | 2012-11-05 | 2016-08-05 | Foundation Medicine, Inc. | 新型ntrk1融合分子及其应用 |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| WO2014118226A1 (en) | 2013-02-01 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyrimidinylamino-indazoles |
| CN103965199B (zh) | 2013-02-02 | 2017-07-07 | 广东东阳光药业有限公司 | 一种芳杂环化合物、包含它的药物组合物及其用途 |
| RU2672910C9 (ru) * | 2013-02-21 | 2019-06-04 | Калитор Сайенсез, ЛЛС | Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы |
| MX2015011898A (es) * | 2013-03-13 | 2016-05-05 | Genentech Inc | Compuestos de pirazolo y usos de los mismos. |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| GB2515785A (en) | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
| SG11201602937UA (en) | 2013-10-17 | 2016-05-30 | Blueprint Medicines Corp | Compositions useful for treating disorders related to kit |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| SMT202200292T1 (it) | 2013-10-25 | 2022-09-14 | Blueprint Medicines Corp | Inibitori del recettore del fattore di crescita dei fibroblasti |
| WO2015108328A1 (ko) * | 2014-01-14 | 2015-07-23 | 주식회사 엘지생명과학 | 대장암 마커로서의 신규 ntrk1 융합유전자 및 이의 용도 |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| WO2015157093A1 (en) * | 2014-04-08 | 2015-10-15 | Rigel Pharmaceuticals, Inc. | 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| KR20240055170A (ko) | 2014-12-15 | 2024-04-26 | 주식회사 씨엠지제약 | 융합된 고리 헤테로아릴 화합물 및 trk 억제제로서의 이들의 용도 |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| JP6800158B2 (ja) * | 2015-02-20 | 2020-12-16 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｇｄｆ−８阻害剤 |
| MX2018001032A (es) | 2015-07-24 | 2018-11-09 | Blueprint Medicines Corp | Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr. |
| WO2017035354A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| JP2019500328A (ja) | 2015-11-19 | 2019-01-10 | ブループリント メディシンズ コーポレイション | Ｎｔｒｋに関連する障害の治療のために有用な化合物及び組成物 |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| CA3020870C (en) | 2016-04-15 | 2024-04-30 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| CN107844168B (zh) | 2017-11-23 | 2020-12-01 | 英业达科技有限公司 | 主板组件及其卡扣装置 |
-
2016
- 2016-11-18 JP JP2018525688A patent/JP2019500328A/ja not_active Ceased
- 2016-11-18 MX MX2018006195A patent/MX2018006195A/es unknown
- 2016-11-18 BR BR112018010024A patent/BR112018010024A8/pt not_active IP Right Cessation
- 2016-11-18 SG SG11201803920TA patent/SG11201803920TA/en unknown
- 2016-11-18 SG SG10201912607SA patent/SG10201912607SA/en unknown
- 2016-11-18 CN CN201680077637.8A patent/CN108431008A/zh active Pending
- 2016-11-18 AR ARP160103546A patent/AR106756A1/es unknown
- 2016-11-18 EP EP16808868.0A patent/EP3377497A1/en not_active Withdrawn
- 2016-11-18 AU AU2016355196A patent/AU2016355196A1/en not_active Abandoned
- 2016-11-18 WO PCT/US2016/062731 patent/WO2017087778A1/en not_active Ceased
- 2016-11-18 HK HK19101858.8A patent/HK1259453A1/zh unknown
- 2016-11-18 KR KR1020187016321A patent/KR20180081790A/ko not_active Withdrawn
- 2016-11-18 RU RU2018122089A patent/RU2018122089A/ru not_active Application Discontinuation
- 2016-11-18 TW TW105137936A patent/TWI733713B/zh not_active IP Right Cessation
- 2016-11-18 US US15/355,425 patent/US10370379B2/en active Active
- 2016-11-18 CA CA3005741A patent/CA3005741A1/en not_active Abandoned
-
2018
- 2018-05-06 IL IL259164A patent/IL259164A/en unknown
- 2018-05-17 PH PH12018501065A patent/PH12018501065A1/en unknown
- 2018-05-28 ZA ZA2018/03530A patent/ZA201803530B/en unknown
-
2019
- 2019-07-31 US US16/527,773 patent/US11059827B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018010024A2 (pt) | 2018-11-21 |
| US10370379B2 (en) | 2019-08-06 |
| US20170145018A1 (en) | 2017-05-25 |
| RU2018122089A (ru) | 2019-12-25 |
| TW201720826A (zh) | 2017-06-16 |
| AU2016355196A1 (en) | 2018-06-21 |
| EP3377497A1 (en) | 2018-09-26 |
| CA3005741A1 (en) | 2017-05-26 |
| JP2019500328A (ja) | 2019-01-10 |
| TWI733713B (zh) | 2021-07-21 |
| BR112018010024A8 (pt) | 2019-02-26 |
| HK1259453A1 (zh) | 2019-11-29 |
| SG10201912607SA (en) | 2020-02-27 |
| US11059827B2 (en) | 2021-07-13 |
| PH12018501065A1 (en) | 2019-01-28 |
| MX2018006195A (es) | 2018-09-05 |
| IL259164A (en) | 2018-06-28 |
| SG11201803920TA (en) | 2018-06-28 |
| WO2017087778A1 (en) | 2017-05-26 |
| US20190382410A1 (en) | 2019-12-19 |
| RU2018122089A3 (es) | 2019-12-30 |
| ZA201803530B (en) | 2021-08-25 |
| CN108431008A (zh) | 2018-08-21 |
| KR20180081790A (ko) | 2018-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106756A1 (es) | Compuestos y composiciones útiles para el tratamiento de trastornos relacionados con ntrk | |
| AR105459A1 (es) | Derivados de pirrolo[2,1-f][1,2,4]triazina útiles para tratar trastornos relacionados con kit y pdfgr | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| MX2018011792A (es) | Compuestos de pirrolotriazina como inhibidores de tyro3, axl y mer (tam). | |
| PE20191613A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| EA202091115A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| MX375902B (es) | Inhibidores de serina/treonina cinasa. | |
| AR100691A1 (es) | Esteroides neuroactivos, composiciones, y usos de los mismos | |
| AR105836A1 (es) | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk | |
| ES2620668T3 (es) | Derivados de amidas y sulfonamidas amido espirocíclicas | |
| EA201892436A1 (ru) | Пиримидиновые соединения в качестве ингибиторов jak киназы | |
| AR089550A1 (es) | Compuestos quimicos | |
| MY199208A (en) | Benzemesulfonamide compounds and their use as therapeutic agents | |
| AR094702A1 (es) | Compuestos de azabencimidazol | |
| MX370906B (es) | Inhibidores de serina/treonina cinasa. | |
| AR078270A1 (es) | Inhibidores de jak (quinasas janus) | |
| AR116880A1 (es) | Compuestos de pirimidinodiona bicíclicos sustituidos con tetrahidropirano, forma polimórfica del mismo y el uso de los mismos para el tratamiento del hcm | |
| EA201891050A1 (ru) | Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2 | |
| AR100715A1 (es) | Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| AR101290A1 (es) | Inhibidores de aldosterona sintasa | |
| BR112017007563A2 (pt) | compostos atropisômeros tricíclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |